Doctor of Podiatric Medicine Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Nicole Mehr

Podiatrist Santa Barbara, CA Doctor of Podiatric Medicine

NPI 1912428574 CMS profile 3277226

101 W Arrellaga St Ste E, Santa Barbara, CA 93101

Open in the dashboard

General payments

$10,282

130 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Nicole Mehr of Santa Barbara, CA is reported in the CMS Open Payments database as having received $10,282 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $227 6
2023 General $213 6
2022 General $3,113 21
2021 General $1,763 30
2020 General $1,865 26
2019 General $3,100 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Mehr
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Nicole Mehr were reported at $0. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Nicole Mehr Podiatrist median Middle half National median
2019 $3,100 $196 $72–$601 $163
2020 $1,865 $118 $38–$335 $114
2021 $1,763 $169 $57–$573 $132
2022 $3,113 $220 $74–$782 $149
2023 $213 $208 $71–$635 $160
2024 $227 $237 $87–$681 $164
2025 $0 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Smith+Nephew, Inc. $2,004 18 payments
  2. Stryker Corporation $1,625 20 payments
  3. Treace Medical Concepts, Inc. $1,087 2 payments
  4. Orthofix Medical, Inc. $1,017 11 payments
  5. Musculoskeletal Transplant Foundation Inc. $801 3 payments
  6. Organogenesis Inc. $737 21 payments
  7. Tenex Health Inc. $577 5 payments
  8. Gemini Medical LLC $460 1 payment
  9. Bioventus LLC $400 8 payments
  10. Wright Medical Technology, Inc. $312 4 payments
  11. Other $1,261 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $6,482 115 payments
  2. Travel and Lodging $3,340 14 payments
  3. Education $460 1 payment
Products named General payments · program years 2019–2024
  1. Versajet $1,234 5 payments
  2. LAPIPLASTY SYSTEM $1,087 2 payments
  3. GRAFIX $983 8 payments
  4. PICO $896 4 payments
  5. RENASYS Touch $896 4 payments
  6. STAR $526 5 payments
  7. TrueLok $503 8 payments
  8. Apligraf $462 15 payments
  9. HOFFMANN $400 5 payments
  10. ANCHORAGE $337 2 payments
  11. Other $7,069 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

47

Median for Podiatry: 160

Drug cost

$1,237

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 16 $876
Clotrimazole Generic 18 $273
Terbinafine Hcl Generic 13 $88

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $168
$168 — —
BEXSERO
  • GlaxoSmithKline, LLC. $19
$19 — —
PEDIARIX
  • GlaxoSmithKline, LLC. $19
$19 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $4
$4 — —
M-M-R II
  • Merck Sharp & Dohme Corporation $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record